Find investors
← Back to all investors
RS
ResearchedAngel Investors

Ryan Shelswell

Head of Australia - Equity and Mezzanine

Angel InvestorsSeed Round
Pitch Ryan

Get their honest, personalized take on your startup.

Sign in to pitch Ryan

At a glance

Full Name
Ryan Shelswell (GAICD)
Title
Head of Australia & New Zealand — Mezzanine & Equity (formerly COO, ICG Asia-Pacific Corporate / Head of Asia Pacific); now Independent Investor & Advisor
Firm
Intermediate Capital Group (ICG plc) — he stepped down in 2022–23 after 12 years
Firm Type
Global alternative-asset manager (private debt, mezzanine, structured/private equity and credit) — not an angel/seed investor (the stub's "Angel Investors / Seed Round" classification appears to be a data error)
Investment Stage
Mid-market and later-stage — mezzanine, subordinated debt, structured equity, and sponsorless/private-equity deals (not seed)
Check Size
Institutional mid-market; ICG's Asia-Pacific Corporate team under him deployed ~US$700m across seven Australia/NZ deals (~US$100m average scale)
Target Company Profile
Established, cash-generative mid-market businesses needing growth, buyout, or expansion capital — including sponsorless (owner-/management-led) deals
Sector Focus
Sector-generalist mid-market; healthcare/teleradiology exposure notable (Everlight Radiology, Canopy Cancer Care)
Geographic Focus
Australia & New Zealand, broader Asia-Pacific
Location
Sydney, New South Wales, Australia

Background

Ryan Shelswell is a Sydney-based private-capital investor who spent most of his career at Intermediate Capital Group (ICG plc), the FTSE-listed global alternative-asset manager. He joined ICG in 2010 to build out its Australia and New Zealand mezzanine and equity business, and over the following decade rose to Head of Australia & New Zealand and, from mid-2018, Head of Asia Pacific — succeeding the retiring Chris Heine — before serving as Chief Operating Officer of ICG's Asia-Pacific Corporate business. He sat on the ICG Asia-Pacific investment committee from 2014 and on the committees of the last four Asia-Pacific regional and Japan domestic funds.

Before ICG, Shelswell was a Director at Pacific Equity Partners, one of Australia's leading buyout private-equity firms, and earlier worked in management consulting at L.E.K. Consulting. He is credited with establishing ICG's "sponsorless" (owner- and management-led, non-PE-sponsored) deal capability across Asia-Pacific and with leading the firm's expansion into Australian private debt, including the ICG Australia Senior Loan Fund. Under his tenure, colleagues noted, ICG Asia-Pacific evolved "from a Hong Kong-based, fly-in fly-out investor to a truly local investor across the region."

Academically, Shelswell holds an MBA from London Business School (Dean's List) and a BSc from Macquarie University (University Medal). He is a Graduate of the Australian Institute of Company Directors (GAICD).

After roughly 12 years, ICG announced that Shelswell had decided to step down from his responsibilities (around 2022–2023). He has since positioned himself on LinkedIn as an Independent Investor & Advisor, and has held board/advisory roles connected to ICG's portfolio and to healthcare businesses.

Investment Thesis & Focus

  • Invests in mid-market, established, cash-generative companies across Australia/NZ and Asia-Pacific — a mezzanine, structured-equity and private-debt mandate, distinct from venture/angel seed investing.
  • Pioneered sponsorless deals at ICG — backing owner-operators and management teams directly rather than only alongside PE sponsors — a differentiated angle for founders/owners who don't want a controlling PE buyer.
  • Comfortable across the capital structure: senior loans (ICG Australia Senior Loan Fund), subordinated/mezzanine debt, and structured equity — flexible instruments to fund growth, buyouts, or recapitalisations.
  • ICG's CEO characterised his edge as "a strong track record in sourcing and executing deals," expanding coverage from sponsor mezzanine into ICG's full strategy set.
  • As an independent, appears to focus on advisory and board roles, with notable healthcare/diagnostics exposure.

Notable Investments

  • Everlight Radiology — international teleradiology group; ICG-backed, where Shelswell served as a director/board member (2020–2021). Sold to UK PE firm Livingbridge in August 2021.
  • ICG Australia Senior Loan Fund — private-debt vehicle he helped launch to expand ICG into Australian/NZ direct lending.
  • ICG Asia-Pacific Corporate Funds (I–IV) — involved across all four flagship regional funds; ~US$700m deployed over seven Australia/NZ deals during his leadership.
  • Canopy Cancer Care — Australasian oncology group; associated with him in a board/advisory capacity per his LinkedIn.

Unlock the full research

Get how to approach them, recent activity, sources, contact links — plus pitch their AI twin for a candid read on your raise.

One-time. Stays unlocked for you.